Crinetics Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 3/4
Crinetics Pharmaceuticals CEO'su R. Struthers, Dec2008 tarihinde atandı, in görev süresi 15.92 yıldır. in toplam yıllık tazminatı $ 5.75M olup, şirket hissesi ve opsiyonları dahil olmak üzere 10.7% maaş ve 89.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.1% ine doğrudan sahiptir ve bu hisseler $ 57.26M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 4.2 yıldır.
Anahtar bilgiler
R. Struthers
İcra Kurulu Başkanı
US$5.7m
Toplam tazminat
| CEO maaş yüzdesi | 10.7% |
| CEO görev süresi | 15.9yrs |
| CEO sahipliği | 1.1% |
| Yönetim ortalama görev süresi | 3.3yrs |
| Yönetim Kurulu ortalama görev süresi | 4.2yrs |
Son yönetim güncellemeleri
Recent updates
We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely
Oct 02
Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech
Aug 12Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation
Jun 01Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data
May 23Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)
Feb 29Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Nov 28Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?
Aug 08Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Dec 31Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
Sep 14Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M
Aug 12We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate
Jun 15Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point
Jun 13CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$278m |
| Jun 30 2024 | n/a | n/a | -US$259m |
| Mar 31 2024 | n/a | n/a | -US$235m |
| Dec 31 2023 | US$6m | US$614k | -US$215m |
| Sep 30 2023 | n/a | n/a | -US$199m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$175m |
| Dec 31 2022 | US$6m | US$590k | -US$164m |
| Sep 30 2022 | n/a | n/a | -US$150m |
| Jun 30 2022 | n/a | n/a | -US$136m |
| Mar 31 2022 | n/a | n/a | -US$119m |
| Dec 31 2021 | US$4m | US$567k | -US$108m |
| Sep 30 2021 | n/a | n/a | -US$98m |
| Jun 30 2021 | n/a | n/a | -US$89m |
| Mar 31 2021 | n/a | n/a | -US$79m |
| Dec 31 2020 | US$4m | US$544k | -US$74m |
| Sep 30 2020 | n/a | n/a | -US$67m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$59m |
| Dec 31 2019 | US$4m | US$542k | -US$50m |
| Sep 30 2019 | n/a | n/a | -US$44m |
| Jun 30 2019 | n/a | n/a | -US$38m |
| Mar 31 2019 | n/a | n/a | -US$31m |
| Dec 31 2018 | US$3m | US$410k | -US$27m |
| Sep 30 2018 | n/a | n/a | -US$21m |
| Jun 30 2018 | n/a | n/a | -US$16m |
| Mar 31 2018 | n/a | n/a | -US$12m |
| Dec 31 2017 | US$385k | US$350k | -US$9m |
Tazminat ve Piyasa: R. 'ın toplam tazminatı ($USD 5.75M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 7.74M ).
Tazminat ve Kazançlar: R. şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
R. Struthers (61 yo)
15.9yrs
Görev süresi
US$5,747,994
Tazminat
Dr. R. Scott Struthers, Ph.D. founded Crinetics Pharmaceuticals, Inc. in November 2008 and serves as its Chief Executive Officer and President since December 2008. He is Chairman at Radionetics Oncology, I...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Founder | 15.9yrs | US$5.75m | 1.1% $ 57.3m | |
| Founder & Chief Scientific Officer | 3.1yrs | US$2.50m | 0.021% $ 1.1m | |
| Chief Financial Officer | 6.8yrs | US$2.51m | 0.062% $ 3.2m | |
| Chief Operating Officer | 3.2yrs | US$2.36m | 0.0044% $ 227.2k | |
| Chief Endocrinologist | 6.4yrs | US$2.16m | 0.014% $ 729.9k | |
| Head of Investor Relations | no data | Veri yok | Veri yok | |
| General Counsel & Corporate Secretary | 3.4yrs | Veri yok | Veri yok | |
| Chief Human Resources Officer | 4.5yrs | Veri yok | Veri yok | |
| Head of Intellectual Property | no data | Veri yok | Veri yok | |
| Chief Business Officer | 2.7yrs | Veri yok | Veri yok | |
| Chief Medical & Development Officer | 2.2yrs | US$3.61m | 0.0023% $ 119.6k | |
| Senior Vice President of Medical Affairs | less than a year | Veri yok | Veri yok |
3.3yrs
Ortalama Görev Süresi
59.5yo
Ortalama Yaş
Deneyimli Yönetim: CRNX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Founder | 16yrs | US$5.75m | 1.1% $ 57.3m | |
| Independent Chairman of the Board | 9.1yrs | US$375.31k | 0.11% $ 5.9m | |
| Independent Director | 6.8yrs | US$348.56k | 0.020% $ 1.0m | |
| Independent Director | 4.2yrs | US$339.56k | 0.0065% $ 336.4k | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 2.8yrs | US$338.56k | 0.012% $ 616.6k | |
| Independent Director | 6.8yrs | US$338.56k | 0.0065% $ 336.4k | |
| Independent Director | 5.3yrs | US$342.31k | 0.0065% $ 336.4k | |
| Independent Director | 2.7yrs | US$330.06k | 0.0065% $ 336.4k | |
| Member of Scientific Advisory Board | 2.6yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 2.6yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 2.6yrs | Veri yok | Veri yok |
4.2yrs
Ortalama Görev Süresi
61yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: CRNX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.2 yıldır).